Frank Tomaka

1.7k total citations
24 papers, 713 citations indexed

About

Frank Tomaka is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Frank Tomaka has authored 24 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 16 papers in Virology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Frank Tomaka's work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (8 papers). Frank Tomaka is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (8 papers). Frank Tomaka collaborates with scholars based in United States, Belgium and Netherlands. Frank Tomaka's co-authors include Tony Vangeneugden, Kiat Ruxrungtham, Martine De Pauw, Tom Van de Casteele, Dénes Bánhegyi, Sabrina Spinosa‐Guzman, Éric Lefebvre, Daniel Berger, José Valdez Madruga and Fredy Suter and has published in prestigious journals such as The Lancet, AIDS and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Frank Tomaka

23 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank Tomaka United States 12 653 446 161 133 80 24 713
José Ramón Santos Spain 17 612 0.9× 487 1.1× 192 1.2× 177 1.3× 50 0.6× 40 796
Nicholaos Bellos United States 11 825 1.3× 621 1.4× 312 1.9× 134 1.0× 58 0.7× 15 936
Sabrina Spinosa‐Guzman United States 12 1.2k 1.8× 917 2.1× 283 1.8× 207 1.6× 109 1.4× 20 1.2k
Magda Opsomer Belgium 12 422 0.6× 293 0.7× 123 0.8× 78 0.6× 51 0.6× 29 517
Gema González‐Pardo Spain 7 348 0.5× 169 0.4× 112 0.7× 128 1.0× 81 1.0× 9 454
Naomi Givens United Kingdom 9 566 0.9× 399 0.9× 200 1.2× 107 0.8× 28 0.3× 17 609
José Valdez Madruga Brazil 7 775 1.2× 600 1.3× 154 1.0× 181 1.4× 58 0.7× 11 829
Jan Fourie United States 10 882 1.4× 678 1.5× 190 1.2× 149 1.1× 62 0.8× 13 939
Roberto Ortiz United States 8 967 1.5× 624 1.4× 250 1.6× 275 2.1× 64 0.8× 17 1.0k
Charles Wakeford United States 7 420 0.6× 264 0.6× 58 0.4× 117 0.9× 55 0.7× 10 503

Countries citing papers authored by Frank Tomaka

Since Specialization
Citations

This map shows the geographic impact of Frank Tomaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Tomaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Tomaka more than expected).

Fields of papers citing papers by Frank Tomaka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Tomaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Tomaka. The network helps show where Frank Tomaka may publish in the future.

Co-authorship network of co-authors of Frank Tomaka

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Tomaka. A scholar is included among the top collaborators of Frank Tomaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Tomaka. Frank Tomaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Custers, Jerome, Maarten Leyssen, Marc Gurwith, et al.. (2020). Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 39(22). 3081–3101. 40 indexed citations
2.
Yanosick, Katherine E., Joan Dragavon, Erin A. Goecker, et al.. (2020). Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infectious Diseases. 8(1). ofaa606–ofaa606. 2 indexed citations
3.
Violari, Avy, Rosa Bologna, Nagalingeswaran Kumarasamy, et al.. (2015). Safety and Efficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients. The Pediatric Infectious Disease Journal. 34(5). e132–e137. 13 indexed citations
4.
Kakuda, Thomas N., Herta Crauwels, Magda Opsomer, et al.. (2015). Darunavir/cobicistat once daily for the treatment of HIV. Expert Review of Anti-infective Therapy. 13(6). 691–704. 11 indexed citations
5.
Orrell, Catherine, Franco Felizarta, Thomas N. Kakuda, et al.. (2015). Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment. 2015. 1–11. 4 indexed citations
6.
Tambuyzer, Lotke, Kim Thys, Annemie Hoogstoel, et al.. (2015). Assessment of Etravirine Resistance in HIV-1-Infected Paediatric Patients using Population and Deep Sequencing: Final Results of the PIANO Study. Antiviral Therapy. 21(4). 317–327. 2 indexed citations
7.
Kakuda, Thomas N., Lorant Leopold, Maarten Timmers, et al.. (2014). Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. International Journal of Clinical Pharmacology and Therapeutics. 52(9). 805–816. 6 indexed citations
8.
Tashima, Karen T., Gordon Crofoot, Frank Tomaka, et al.. (2014). Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Research and Therapy. 11(1). 39–39. 48 indexed citations
9.
Kakuda, Thomas N., et al.. (2014). Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. Journal of Antimicrobial Chemotherapy. 69(10). 2591–2605. 24 indexed citations
10.
Kakuda, Thomas N., Lorant Leopold, Steven Nijs, et al.. (2014). Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial. The Journal of Clinical Pharmacology. 54(5). 563–573. 10 indexed citations
11.
Orrell, Catherine, Franco Felizarta, Thomas N. Kakuda, et al.. (2013). Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial. 1 indexed citations
12.
Overton, Edgar T., et al.. (2012). Effect of Darunavir on Lipid Profile in HIV-Infected Patients. HIV Clinical Trials. 13(5). 256–270. 27 indexed citations
13.
Adda, Nathalie, Doug J. Bartels, Linda Gritz, et al.. (2012). Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 11(2). 193–195. 8 indexed citations
14.
Bánhegyi, Dénes, Christine Katlama, Clóvis Arns da Cunha, et al.. (2012). Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN. Current HIV Research. 10(2). 171–181. 39 indexed citations
15.
Cahn, Pedro, Jan Fourie, Beatriz Grinsztejn, et al.. (2011). Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 25(7). 929–939. 75 indexed citations
16.
Sekar, Vanitha, Sabrina Spinosa‐Guzman, Els De Paepe, et al.. (2010). Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment. Clinical Pharmacokinetics. 49(5). 343–350. 17 indexed citations
17.
Sekar, Vanitha, Frank Tomaka, Éric Lefebvre, et al.. (2010). Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone. The Journal of Clinical Pharmacology. 51(2). 271–278. 16 indexed citations
18.
Arastéh, Keikawus, Patrick Yéni, Anton Pozniak, et al.. (2009). Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antiviral Therapy. 14(6). 859–864. 68 indexed citations
19.
Mathias, Anita, John E. Hinkle, Gong Shen, et al.. (2008). Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 49(2). 156–162. 19 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Ramón Santos Breakdown of academic impact, for papers by Nicholaos Bellos Breakdown of academic impact, for papers by Sabrina Spinosa‐Guzman Breakdown of academic impact, for papers by Magda Opsomer Breakdown of academic impact, for papers by Gema González‐Pardo Breakdown of academic impact, for papers by Naomi Givens Breakdown of academic impact, for papers by José Valdez Madruga Breakdown of academic impact, for papers by Jan Fourie Breakdown of academic impact, for papers by Roberto Ortiz Breakdown of academic impact, for papers by Charles Wakeford
Rankless by CCL
2026